Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP-Reference-Cited by-同舟云学术

Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP

Published:2021-04-28 Issue:7 Volume:218 Page:
ISSN:0022-1007
Container-title:Journal of Experimental Medicine
language:en
Short-container-title:

Author:

Solforosi Laura¹^ORCID,Kuipers Harmjan¹^ORCID,Jongeneelen Mandy¹^ORCID,Rosendahl Huber Sietske K.¹^ORCID,van der Lubbe Joan E.M.¹^ORCID,Dekking Liesbeth¹^ORCID,Czapska-Casey Dominika N.¹^ORCID,Izquierdo Gil Ana¹,Baert Miranda R.M.¹^ORCID,Drijver Joke¹^ORCID,Vaneman Joost¹^ORCID,van Huizen Ella¹^ORCID,Choi Ying¹^ORCID,Vreugdenhil Jessica¹^ORCID,Kroos Sanne¹^ORCID,de Wilde Adriaan H.¹^ORCID,Kourkouta Eleni¹^ORCID,Custers Jerome¹^ORCID,van der Vlugt Remko¹^ORCID,Veldman Daniel¹^ORCID,Huizingh Jeroen¹^ORCID,Kaszas Krisztian¹^ORCID,Dalebout Tim J.²^ORCID,Myeni Sebenzile K.²^ORCID,Kikkert Marjolein²^ORCID,Snijder Eric J.²^ORCID,Barouch Dan H.³^ORCID,Böszörményi Kinga P.⁴^ORCID,Stammes Marieke A.⁴^ORCID,Kondova Ivanela⁴^ORCID,Verschoor Ernst J.⁴^ORCID,Verstrepen Babs E.⁴^ORCID,Koopman Gerrit⁴^ORCID,Mooij Petra⁴^ORCID,Bogers Willy M.J.M.⁴^ORCID,van Heerden Marjolein⁵^ORCID,Muchene Leacky¹^ORCID,Tolboom Jeroen T.B.M.¹^ORCID,Roozendaal Ramon¹^ORCID,Brandenburg Boerries¹^ORCID,Schuitemaker Hanneke¹^ORCID,Wegmann Frank¹^ORCID,Zahn Roland C.¹^ORCID

Affiliation:

1. Janssen Vaccines and Prevention B.V., Leiden, Netherlands

2. Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands

3. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

4. Biomedical Primate Research Centre, Rijswijk, Netherlands

5. Non-Clinical Safety Toxicology/Pathology, Janssen Research and Development, Beerse, Belgium

Abstract

Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve the magnitude and durability of immunity and protective efficacy. We assessed one- and two-dose regimens of the Ad26.COV2.S vaccine candidate in adult and aged nonhuman primates (NHPs). A two-dose Ad26.COV2.S regimen induced higher peak binding and neutralizing antibody responses compared with a single dose. In one-dose regimens, neutralizing antibody responses were stable for at least 14 wk, providing an early indication of durability. Ad26.COV2.S induced humoral immunity and T helper cell (Th cell) 1–skewed cellular responses in aged NHPs that were comparable to those in adult animals. Aged Ad26.COV2.S-vaccinated animals challenged 3 mo after dose 1 with a SARS-CoV-2 spike G614 variant showed near complete lower and substantial upper respiratory tract protection for both regimens. Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen.

Funder

US Department of Health and Human Services

Biomedical Advanced Research and Development Authority

Publisher

Rockefeller University Press

Subject

Immunology,Immunology and Allergy

Link

http://rupress.org/jem/article-pdf/doi/10.1084/jem.20202756/1414179/jem_20202756.pdf

Reference67 articles.

1. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D;Abbink;J. Virol.,2007

2. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults;Anderson;N. Engl. J. Med.,2020